Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab-based immunotherapy combinations versus dostarlimab monotherapy in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
2023-503428-24-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of dostarlimab, GSK4381562, nelistotug and etigilimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GSK. Primary endpoint: Confirmed objective response rate. Planned start Jan 2024; status: authorised.
02
Drugs
dostarlimabGSK4381562nelistotugetigilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-503428-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503428-24-00.